Novo Nordisk gains US approval of its new diabetes drug  

2010.01.28
Novo Nordisk has received marketing authorisation of Victoza for the treatment of type 2 diabetes in adults from the US Food and Drug Administration
Danish healthcare company Novo Nordisk has received the long-awaited marketing authorisation of Victoza (liraglutide) for the treatment of type 2 diabetes in adults from the US Food and Drug Administration (FDA), reports national daily newspaper Jyllands-Posten.

Victoza is the brand name approved in the US and Europe for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue.

Analyst Rune Majlund Dahl of Sydbank recently told national newspaper Berlingske Tidende that he estimates the approval of Victoza in the US will generate an additional turnover of DKK 12-18bn (USD 2.3-3.4bn) when the product is fully taken up by the market by 2018.
 
Lars Rebien Sørensen, president and CEO of Novo Nordisk says in a press release: "The US approval of Victoza represents a major advance in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe."
 
Novo Nordisk plans to launch Victoza on the US market within weeks.
 
With headquarters in Denmark, Novo Nordisk employs more than 29,000 people in 81 countries, and markets its products in 179 countries. The company's B shares are listed on the stock exchanges in Copenhagen and London.
 
Link > Novo Nordisk             

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×